Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. develops cancer immunotherapy programs using its AI/ML-powered Unigen computational discovery capabilities to identify drug targets and biological pathways. News about CGEN commonly covers clinical and preclinical immuno-oncology programs, including COM701, COM902, rilvegostomig and GS-0321, as well as updates tied to immune-checkpoint targets such as PVRIG, TIGIT and IL-18 binding protein.
Recurring company developments include quarterly and annual financial results, corporate updates, scientific conference presentations, clinical data disclosures, partnership activity with AstraZeneca and Gilead, royalty and license arrangements, and board or leadership changes. Compugen's ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
Compugen Ltd. (Nasdaq: CGEN) has appointed Alberto Sessa as the new Chief Financial Officer (CFO), effective November 1, 2022. Sessa brings over 30 years of experience in finance, including roles in leading financing, investor relations, and business development. His previous positions include acting CFO at several startups and CFO at Allot, where he contributed to the company's growth. This leadership change aims to bolster Compugen's strategic ambitions and enhance stakeholder value as the company accelerates its cancer immunotherapy pipeline.
Compugen Ltd. (Nasdaq: CGEN) has announced that Yaron Turpaz, Ph.D., Senior Vice President and Senior Advisor, will speak at the Fierce Biotech Summit on September 20, 2022, in Boston. The panel discussion will focus on leveraging artificial intelligence (AI) and machine learning (ML) to enhance drug discovery and development. Compugen specializes in cancer immunotherapy and has developed two proprietary product candidates: COM701 and COM902. Additional details about the event can be found here.
Compugen Ltd. (CGEN) announced the Japan Patent Office granted a new patent for its anti-PVRIG antibody, COM701, which expands its intellectual property coverage to include Japan. The patent, No. 2017-562952, safeguards COM701's composition and use, enhancing its existing patents in the U.S. and Europe. This strategic move is aimed at solidifying the company's position in the competitive cancer immunotherapy market. With a patent expiration date set for no earlier than 2036, Compugen is poised to leverage this protection as it advances its innovative pipeline.
Compugen Ltd. (NASDAQ: CGEN) announced the granting of a new patent from the European Patent Office for anti-PVRIG antibodies aimed at cancer treatment. The patent, European Patent No. 3 653 221, secures broad protection for the use of COM701, expanding its application to any anti-PVRIG antibody that activates T and NK cells. The patent is set to expire no earlier than February 2036. This strategic move enhances Compugen’s position in the competitive cancer immunotherapy market and supports its ongoing clinical programs targeting multiple immune checkpoints.
Compugen Ltd. (CGEN) announced a strategic shift, prioritizing microsatellite stable-colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC) for development. The company will wind down its Phase 1 cohort expansion studies and conclude its collaboration with Bristol Myers Squibb. Compugen anticipates extending its cash runway through the end of 2024, with approximately $97 million in available cash. R&D expenses remain stable, with a net loss of approximately $9.1 million reported for Q2 2022. The company aims to present further data and study designs in Q4 2022.
Compugen Ltd. (Nasdaq: CGEN) will announce its second quarter financial results on August 4, 2022, before U.S. markets open. A conference call and webcast will take place at 8:30 AM ET for management to discuss the results and provide corporate updates. Compugen is a clinical-stage cancer immunotherapy company focused on computational target discovery, featuring proprietary drug candidates like COM701 and COM902, both in Phase 1 trials. Their partnership with Bayer and AstraZeneca also highlights their innovative drug development.
Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy firm, announced its management team's upcoming presentations at industry conferences in Europe. The first event is the 10th Antibody Industrial Symposium in Montpellier, France, on June 28, 2022, featuring Pierre Ferré discussing PVRIG and TIGIT immune checkpoint blockade. The second event is Immuno UK in London on September 29-30, 2022, with Eran Ophir presenting on immunotherapy resistance. Presentation slides will be available on their website.
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced its participation in two upcoming investor conferences. The Jefferies Healthcare Conference will take place in New York City on June 8, 2022, with a fireside chat scheduled for 1:30 PM ET. The JMP Securities Life Sciences Conference is also in New York City on June 15, 2022, at 9:00 AM ET. Live webcasts of both events will be available on Compugen's Investor Relations website.
Compugen Ltd. (CGEN) reported its Q1 2022 financial results, noting a cash balance of $107 million, down from $118 million in Q4 2021. The company continues to execute on its clinical strategy with ongoing Phase 1 studies for COM701 and COM902, aiming for initial data in Q4 2022 related to MSS CRC. COM902 demonstrated a disease control rate of 50%, while R&D expenses were $7.2 million, slightly down year-over-year. Despite a net loss of $9.7 million, the company expects sufficient funds to sustain operations into 2024.
Compugen Ltd. (Nasdaq: CGEN) announced that CFO and COO Ari Krashin will depart the company in August 2022 to pursue other interests. His departure is unrelated to the company's operations or policies. Compugen is a clinical-stage cancer immunotherapy firm known for its predictive computational discovery capabilities, developing drug candidates like COM701 and COM902, targeting various solid tumors. The company maintains partnerships with Bayer and AstraZeneca for its therapeutic programs. Compugen is headquartered in Israel with additional offices in South San Francisco.